EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence and risk factors of cytomegalovirus reactivation in critically Ill patients with COVID-19 pneumonia

Tanapat Tassaneeyasin iD, Somnuek Sungkanuparph iD, Sirawat Srichatrapimuk, Attawit Charoensri, Kanin Thammavaranucupt iD, Kulapong Jayanama, Suppachok Kirdlarp iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0303995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tanapat Tassaneeyasin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand. Hauptthemen laut MEDLINE: COVID-19, Critical Illness, Cytomegalovirus Infections, Cytomegalovirus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds In critically ill patients with COVID-19, secondary infections are potentially life-threatening complications. This study aimed to determine the prevalence, clinical characteristics, and risk factors of CMV reactivation among critically ill immunocompetent patients with COVID-19 pneumonia.

Methods

A retrospective cohort study was conducted among adult patients who were admitted to ICU and screened for quantitative real-time PCR for CMV viral load in a tertiary-care hospital during the third wave of the COVID-19 outbreak in Thailand. Cox regression models were used to identify significant risk factors for developing CMV reactivation.

Results

A total of 185 patients were studied; 133 patients (71.9%) in the non-CMV group and 52 patients (28.1%) in the CMV group. Of all, the mean age was 64.7±13.3 years and 101 patients (54.6%) were males. The CMV group had received a significantly higher median cumulative dose of corticosteroids than the non-CMV group (301 vs 177 mg of dexamethasone, p 0.05). The 90-day mortality rate for all patients was 29.1%, with a significant difference between the CMV group and the non-CMV group (42.3% vs. 24.1%, p = 0.014). Median length of stay was longer in the CMV group than non-CMV group (43 vs 24 days, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Critical IllnessCytomegalovirus InfectionsCytomegalovirusHumansMaleMiddle AgedFemaleRisk FactorsAgedRetrospective StudiesPrevalenceSARS-CoV-2Virus ActivationThailandViral Load

Autor:innen und Institutionen

  • Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.

ORCID-Profile: Tanapat Tassaneeyasin, Somnuek Sungkanuparph, Kanin Thammavaranucupt, Suppachok Kirdlarp

Zitieren

APA

Tassaneeyasin, T., Sungkanuparph, S., Srichatrapimuk, S., Charoensri, A., Thammavaranucupt, K., Jayanama, K., & Kirdlarp, S. (2024). Prevalence and risk factors of cytomegalovirus reactivation in critically Ill patients with COVID-19 pneumonia. PLOS ONE. https://doi.org/10.1371/journal.pone.0303995

Vancouver

Tassaneeyasin T, Sungkanuparph S, Srichatrapimuk S, Charoensri A, Thammavaranucupt K, Jayanama K, et al. Prevalence and risk factors of cytomegalovirus reactivation in critically Ill patients with COVID-19 pneumonia. PLOS ONE. 2024. doi:10.1371/journal.pone.0303995

BibTeX
@article{Tassaneeyasin2024,
  author = {Tassaneeyasin, Tanapat and Sungkanuparph, Somnuek and Srichatrapimuk, Sirawat and Charoensri, Attawit and Thammavaranucupt, Kanin and Jayanama, Kulapong and Kirdlarp, Suppachok},
  title = {Prevalence and risk factors of cytomegalovirus reactivation in critically Ill patients with COVID-19 pneumonia},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0303995}
}
Kostenlos starten →